Parabilis Medicines Financial Statements
NASDAQ: PBLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Parabilis Medicines has no annual income statement on file yet, so quarterly figures are shown instead.
Parabilis Medicines revenue and earnings
In the quarter ended Jun 30, 2026, Parabilis Medicines generated $148,000 in revenue. Parabilis Medicines reported a net loss of $52.5 million. Operating margin was -34382.4%.
Diluted earnings per share came in at -$2.32.
Summary generated from market data by MetaCap's automated system. Methodology
Parabilis Medicines income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q? 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Revenue | 148.00K | — | 0 | — |
| Revenue growth (YoY) | — | — | — | — |
| Operating Expenses | 51.03M | — | 36.52M | — |
| Research & Development | 39.38M | — | 30.13M | — |
| Operating Income | -50.89M | — | -36.52M | — |
| Interest Expense | 210.00K | — | 396.00K | — |
| Other Income (Expense) | -1.58M | — | 1.71M | — |
| Net Income | -52.46M | -45.32M | -34.81M | -38.33M |
| Net Income growth (YoY) | — | — | — | — |
| EPS (Basic) | -2.32 | — | -22.28 | — |
| EPS (Diluted) | -2.32 | — | -22.28 | — |
| Shares Outstanding (Basic) | 28.91M | — | 2.02M | — |
| Shares Outstanding (Diluted) | 28.91M | — | 2.02M | — |
| EBITDA | -50.29M | — | -36.32M | — |
| Operating Margin | -34382.43% | — | — | — |
| Net Margin | -35447.97% | — | — | — |
This table shows 4 quarterly periods of Parabilis Medicines's income statement, from Q2 2026 back to Q? 2025, across 14 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow PBLS's reporting calendar. What is a income statement?